MX347303B - Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion. - Google Patents
Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion.Info
- Publication number
- MX347303B MX347303B MX2008011279A MX2008011279A MX347303B MX 347303 B MX347303 B MX 347303B MX 2008011279 A MX2008011279 A MX 2008011279A MX 2008011279 A MX2008011279 A MX 2008011279A MX 347303 B MX347303 B MX 347303B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- factor
- derivatives
- cells
- human embryonic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
Abstract
La presente invención se refiere a una composición farmacéutica para el tratamiento de enfermedades, trastornos o condiciones, caracterizad porque comprende una cantidad terapéuticamente eficaz de células madre embrionarias humanas (hES) y/o sus derivados están libres de productos animales no humanos, células alimentadoras, factores de crecimiento, factor inhibidor de leucemia, factor de crecimiento de fibroblastos, suplementos vitamínicos, factor de Steel asociado a membrana, factor de Steel soluble y medios acondicionados, en donde las células hEs y/o sus derivados están suspendidos en una solución biocompatible farmacéuticamente aceptable, en donde los derivados de células hEs se seleccionan del grupo que consiste de progenitores de células madre hematopoyéticas, progenitores de células madre neuronales, progenitores de células madre mesenquimáticas, progenitores de células madre productoras de insulina, progenitores de células madre de hepatocitos, progenitores de células madre cardiacas, progenitores de células madre epiteliales y mezclas de los mismo, y en donde las células hEs y/o sus derivados de los mismo, y en donde las células hEs y/o sus derivados se expanden por un método que comprende: a) introducir células hES y/o sus derivados en un medio de cultivo que consiste de medio esencial mínimo, una progestina y un agonista de gonadotropina coriónica humana ß b) incubar las células hEs y/o sus derivados a una temperatura de 34°C a 38°C en un ambiente de 3.5 % a 6% de dióxido de carbono durante 12 horas a 48 horas. Un método para expandir las células embrionarias, para diferenciarlas para almacenarlas, un método para preparar de dichas células, y sus médicos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN582DE2006 | 2006-03-07 | ||
IN1500DE2006 | 2006-06-26 | ||
US84435006P | 2006-09-14 | 2006-09-14 | |
PCT/IB2007/002292 WO2007141657A2 (en) | 2006-03-07 | 2007-03-06 | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2008011279A MX2008011279A (es) | 2008-11-25 |
MX347303B true MX347303B (es) | 2017-04-21 |
Family
ID=54150153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008011279A MX347303B (es) | 2006-03-07 | 2007-03-06 | Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion. |
Country Status (23)
Country | Link |
---|---|
US (9) | US10545135B2 (es) |
EP (11) | EP1993575B1 (es) |
JP (2) | JP5649786B2 (es) |
KR (2) | KR101505202B1 (es) |
CN (2) | CN101420964A (es) |
AP (1) | AP2949A (es) |
AU (1) | AU2007257594B2 (es) |
BR (1) | BRPI0708576A2 (es) |
CA (1) | CA2644922C (es) |
CR (1) | CR10345A (es) |
CU (1) | CU20080161A7 (es) |
DK (1) | DK1993575T3 (es) |
EA (1) | EA027648B9 (es) |
EC (1) | ECSP088799A (es) |
GE (1) | GEP20135796B (es) |
IL (1) | IL193702A (es) |
MA (1) | MA30323B1 (es) |
MX (1) | MX347303B (es) |
MY (1) | MY154677A (es) |
NO (1) | NO20084181L (es) |
NZ (2) | NZ571127A (es) |
PH (1) | PH12014501028A1 (es) |
WO (1) | WO2007141657A2 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY154677A (en) | 2006-03-07 | 2015-07-15 | Shroff Geeta | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
ATE530638T1 (de) | 2007-04-26 | 2011-11-15 | Univ Ramot | Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut |
JP5567476B2 (ja) * | 2007-05-28 | 2014-08-06 | モナッシュ ユニバーシティ | 慢性肺疾患の治療 |
US20090291061A1 (en) * | 2008-05-21 | 2009-11-26 | Riordan Neil H | Stem cell therapy for blood vessel degeneration |
ES2556630T3 (es) * | 2008-06-11 | 2016-01-19 | Fresenius Medical Care Deutschland Gmbh | Medio condicionado para células progenitoras de hígado |
US20100010087A1 (en) * | 2008-07-10 | 2010-01-14 | Hong John J | Methods for Inducing Stem Cell Migration and Specialization with EC-18 |
JP2012508584A (ja) * | 2008-11-14 | 2012-04-12 | ヴィアサイト,インコーポレイテッド | ヒト多能性幹細胞由来膵臓細胞のカプセル化 |
GB201111244D0 (en) * | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
US8377432B2 (en) * | 2009-09-02 | 2013-02-19 | Khay-Yong Saw | Method and composition for neochondrogenesis |
US8741649B2 (en) | 2009-09-04 | 2014-06-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for enhancing genome stability and telomere elongation in embryonic stem cells |
US20120201791A1 (en) * | 2009-10-15 | 2012-08-09 | Tai June Yoo | Methods of treating diseases or conditions using mesenchymal stem cells |
WO2011070974A1 (ja) * | 2009-12-07 | 2011-06-16 | 国立大学法人名古屋大学 | 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤 |
WO2011127113A1 (en) * | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
WO2011145110A1 (en) | 2010-05-15 | 2011-11-24 | Subhadra Dravida | A novel cord blood plasma nutrient formulation and a method for the preparation thereof |
AU2011326767B2 (en) * | 2010-11-10 | 2016-02-11 | Prokidney | Injectable formulations for organ augmentation |
FR2986537B1 (fr) * | 2012-02-07 | 2014-03-28 | Oreal | Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales |
CA2870466A1 (en) * | 2012-04-16 | 2013-10-24 | The Regents Of The University Of California | Ocular therapeutics using embryonic stem cell microvesicles |
WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
WO2014116786A1 (en) * | 2013-01-25 | 2014-07-31 | Zietchick Research Institute,Llc | Use of human chorionic gonadotropin to treat cerebral palsy and/or its co-morbidities |
CN103961373A (zh) | 2013-02-04 | 2014-08-06 | 西比曼生物科技(上海)有限公司 | 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用 |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
ITMI20130513A1 (it) * | 2013-04-05 | 2014-10-06 | Euroclone S P A | Metodo diagnostico per patologie autoimmuni del fegato |
CA2949171A1 (en) | 2014-05-16 | 2015-11-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
KR101686315B1 (ko) | 2015-01-09 | 2016-12-13 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법 |
KR102036029B1 (ko) | 2015-03-11 | 2019-10-24 | 이화여자대학교 산학협력단 | 골수 부전 예방 또는 치료용 조성물 |
KR20160109356A (ko) | 2015-03-11 | 2016-09-21 | 이화여자대학교 산학협력단 | 자가 면역 질환 예방 또는 치료용 조성물 |
KR20160109358A (ko) | 2015-03-11 | 2016-09-21 | 이화여자대학교 산학협력단 | 면역 질환 예방 또는 치료용 조성물 |
KR101885122B1 (ko) | 2015-03-26 | 2018-09-11 | 이화여자대학교 산학협력단 | 분화촉진 및 지속형 스페로이드 형태의 편도 유래 줄기세포의 배양 방법 |
DK3303564T3 (da) | 2015-06-01 | 2022-04-04 | Memorial Sloan Kettering Cancer Center | Fremgangsmåder til in vitro-differentiering af midthjerne-dopamin-(mda)-neuroner |
KR20180105236A (ko) | 2016-02-05 | 2018-09-27 | 메모리얼 슬로안-케터링 캔서 센터 | 줄기 세포-유래 외배엽 계통 전구체의 분화 방법 |
CN105749254A (zh) * | 2016-02-28 | 2016-07-13 | 深圳爱生再生医学科技有限公司 | 用于治疗血管性痴呆的干细胞制剂及其制备方法和应用 |
GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
EP3464567A4 (en) | 2016-05-27 | 2020-01-08 | Memorial Sloan Kettering Cancer Center | METHODS FOR DIFFERENTIATION OF STEM CELL-DERIVED PROPERTIES |
US20180242590A1 (en) * | 2016-09-23 | 2018-08-30 | Peter Friedman | Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health |
CN106177918A (zh) * | 2016-09-30 | 2016-12-07 | 广州赛莱拉干细胞科技股份有限公司 | 一种间充质干细胞注射液及其制备方法和应用 |
KR102208889B1 (ko) * | 2017-01-31 | 2021-01-27 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 다능성줄기세포의 분화 제어 방법 |
WO2019040790A1 (en) | 2017-08-23 | 2019-02-28 | Merakris Therapeutics, Llc | COMPOSITIONS CONTAINING AMNIOTIC COMPONENTS AND METHODS FOR THEIR PREPARATION AND USE |
KR102130493B1 (ko) | 2018-07-11 | 2020-07-06 | 이화여자대학교 산학협력단 | 건선 예방 또는 치료용 조성물 |
KR102089476B1 (ko) | 2018-07-11 | 2020-03-16 | 이화여자대학교 산학협력단 | 피부 염증 질환 예방 또는 치료용 조성물 |
KR20190120141A (ko) | 2019-10-16 | 2019-10-23 | 이화여자대학교 산학협력단 | 골수 부전 예방 또는 치료용 조성물 |
KR20210119766A (ko) * | 2020-03-25 | 2021-10-06 | 서울대학교병원 | 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물 |
CN117500916A (zh) | 2021-04-16 | 2024-02-02 | 博恩赛尔公司 | 制备、扩增和纯化中脑多巴胺能祖细胞的方法 |
CN113116933A (zh) * | 2021-04-26 | 2021-07-16 | 河北医科大学第四医院 | 一种防治糖尿病足的干细胞组合物及其应用 |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744347A (en) | 1987-01-16 | 1998-04-28 | Ohio University Edison Biotechnology Institute | Yolk sac stem cells and their uses |
JP2740320B2 (ja) | 1988-08-04 | 1998-04-15 | アムラド・コーポレイション・リミテッド | 胚幹細胞のインビトロ増殖 |
US5256560A (en) | 1988-10-07 | 1993-10-26 | University Of Saskatchewan | Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells |
US5411883A (en) | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5840580A (en) | 1990-05-01 | 1998-11-24 | Becton Dickinson And Company | Phenotypic characterization of the hematopoietic stem cell |
US5622853A (en) | 1990-05-01 | 1997-04-22 | Becton Dickinson And Company | T lymphocyte precursor |
ATE181746T1 (de) | 1990-09-10 | 1999-07-15 | Takeda Chemical Industries Ltd | Menschlicher rezeptor für luteinisierendes hormon und choriongonadotropin |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US6410320B1 (en) | 1992-03-02 | 2002-06-25 | The University Of Michigan | Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules |
AU658065B2 (en) | 1992-03-23 | 1995-03-30 | Nexell Therapeutics Inc. | (In vitro)-derived human neutrophil precursor cells |
WO1994000484A1 (en) | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
SG86980A1 (en) | 1992-11-16 | 2002-03-19 | Applied Immunesciences | Pluripotential quiescent stem cell population |
DE4240635C2 (de) | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren |
AU685506B2 (en) | 1993-08-25 | 1998-01-22 | Systemix, Inc. | Method for producing a highly enriched population of hematopoietic stem cells |
US5453457A (en) | 1993-11-12 | 1995-09-26 | Bayer Corporation | Gamma-radiation-resistant polycarbonate composition |
US5972627A (en) | 1994-06-15 | 1999-10-26 | Systemix, Inc. | Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby |
US5650317A (en) | 1994-09-16 | 1997-07-22 | Michigan State University | Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5821108A (en) | 1995-04-07 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker |
US5876956A (en) | 1995-05-15 | 1999-03-02 | Johns Hopkins University School Of Medicine | Methods for identification or purification of cells containing an enzymatic intracellular marker |
US5908782A (en) | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
US6517872B1 (en) | 1995-06-12 | 2003-02-11 | Yeda Research And Development Co., Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells |
US5753505A (en) | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
GB9514816D0 (en) | 1995-07-19 | 1995-09-20 | Ucli Ltd | Substances and their medical use |
US5858782A (en) | 1995-11-13 | 1999-01-12 | Regents Of The University Of Michigan | Functional human hematopoietic cells |
US5997871A (en) | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
US6969608B1 (en) | 1996-08-26 | 2005-11-29 | Mcgill University | Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors |
US6890724B2 (en) | 1996-09-06 | 2005-05-10 | California Institute Of Technology | Methods and compositions for neural progenitor cells |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
CA2216439A1 (en) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
US6734015B1 (en) | 1997-07-04 | 2004-05-11 | University Of Utah Research Foundation | Isolation of lineage-restricted neuronal precursors |
US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
EP1034288A4 (en) | 1997-12-04 | 2002-11-27 | Univ Duke | METHODS FOR INSULATION AND USE OF CD7 + CD34-LIN HEMATOPOETIC CELLS |
EP1060242A4 (en) | 1998-01-23 | 2003-09-17 | Imclone Systems Inc | PURIFIED POPULATIONS OF STEM CELLS |
AUPP244498A0 (en) * | 1998-03-18 | 1998-04-09 | Medvet Science Pty. Ltd. | Keratinocyte stem cells |
US6812027B2 (en) | 1998-03-25 | 2004-11-02 | Cornell Research Foundation, Inc. | Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain |
US6835567B1 (en) | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
ATE368731T1 (de) | 1998-05-29 | 2007-08-15 | Osiris Therapeutics Inc | Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen |
US6129911A (en) | 1998-07-10 | 2000-10-10 | Rhode Island Hospital, A Lifespan Partner | Liver stem cell |
US6913925B1 (en) | 1998-08-12 | 2005-07-05 | Signal Pharmaceuticals Llc | Human mesencephalon cell lines and methods of use therefor |
DE19837438A1 (de) | 1998-08-18 | 2000-02-24 | Biotechnolog Forschung Gmbh | Rekombinante Humanzelle für Knochen- und Knorpelzellbildung |
US6767737B1 (en) | 1998-08-31 | 2004-07-27 | New York University | Stem cells bearing an FGF receptor on the cell surface |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
WO2000035464A1 (fr) | 1998-12-16 | 2000-06-22 | Tsentr Embrionalnykh Tkanei 'emcell' | Procede permettant de soigner des personnes a l'aide de suspensions cellulaires de tissus embryonnaires |
BR0008468A (pt) | 1999-02-24 | 2002-02-05 | Novo Nordisk As | Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos |
US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
WO2000065068A1 (en) | 1999-04-23 | 2000-11-02 | Ceptyr, Inc. | Dsp-10 dual-specificity map kinsase phosphatase |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6761883B2 (en) | 1999-06-29 | 2004-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
DE60036470T2 (de) | 1999-06-29 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto | Untereinheiten von myeloid-progenitorzellen von säugern |
US6872389B1 (en) | 1999-07-08 | 2005-03-29 | Rhode Island Hospital | Liver stem cell |
US6043235A (en) | 1999-07-21 | 2000-03-28 | Research Triangle Institute | 11β-aryl-17, 17-spirothiolane-substituted steroids |
WO2002064748A2 (en) | 2001-02-14 | 2002-08-22 | Furcht Leo T | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
WO2001019379A2 (en) | 1999-09-14 | 2001-03-22 | Children's Medical Center Corporation, The | Methods for treating muscular dystrophy with bone marrow cells |
WO2001019966A2 (en) * | 1999-09-14 | 2001-03-22 | Children's Medical Center Corporation, The | Isolation of muscle-derived stem cells and uses therefor |
US20030082155A1 (en) | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US6753153B2 (en) | 1999-12-13 | 2004-06-22 | The Scripps Research Institute | Markers for identification and isolation of pancreatic islet α and β progenitors |
US6416999B1 (en) | 2000-04-07 | 2002-07-09 | Raven Biotechnologies, Inc. | Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
US20020005205A1 (en) * | 2000-04-25 | 2002-01-17 | Barry Francis P. | Joint repair using mesenchymal stem cells |
NL1017973C2 (nl) | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
US6936281B2 (en) | 2001-03-21 | 2005-08-30 | University Of South Florida | Human mesenchymal progenitor cell |
AU785428B2 (en) * | 2000-08-30 | 2007-05-17 | Maria Biotech Co., Ltd | Human embryonic stem cells derived from frozen-thawed embryo |
US20040071665A1 (en) | 2000-09-05 | 2004-04-15 | Yong-Fu Xiao | Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
US6458588B1 (en) | 2001-01-31 | 2002-10-01 | The General Hospital Corporation | Renal stem cells and uses thereof |
US6852532B2 (en) | 2001-03-21 | 2005-02-08 | University Of Utah Research Foundation | Method of isolating human neuroepithelial precursor cells from human fetal tissue |
WO2002079457A1 (en) * | 2001-03-29 | 2002-10-10 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
US20030017587A1 (en) | 2001-07-18 | 2003-01-23 | Rader William C. | Embryonic stem cells, clinical applications and methods for expanding in vitro |
DE10139783C1 (de) * | 2001-08-14 | 2003-04-17 | Transtissue Technologies Gmbh | Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung |
US7527974B2 (en) * | 2001-11-06 | 2009-05-05 | Shanghai Second Medical University | Embryonic stem cells derived from human somatic cell—rabbit oocyte NT units |
EP1442115B9 (en) | 2001-11-15 | 2009-12-16 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
JP2005510232A (ja) | 2001-11-26 | 2005-04-21 | アドバンスド セル テクノロジー、インク. | 再プログラムされたヒト体細胞核ならびに自系および同系なヒト幹細胞の製造および使用方法 |
WO2003077865A2 (en) | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Methods and compositions for directing cells to target organs |
US20040009589A1 (en) * | 2002-03-26 | 2004-01-15 | Shulamit Levenberg | Endothelial cells derived from human embryonic stem cells |
US7285415B2 (en) * | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
ATE536405T1 (de) * | 2002-07-25 | 2011-12-15 | Scripps Research Inst | Hämatopoetische stammzellen und verfahren zur behandlung von neovaskulären augenerkrankungen damit |
HK1055058A2 (en) | 2002-10-11 | 2003-12-05 | Ligand Pharm Inc | 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
WO2004032881A2 (en) * | 2002-10-11 | 2004-04-22 | Novocell, Inc. | Implantation of encapsulated biological materials for treating diseases |
AU2003285172A1 (en) * | 2002-11-08 | 2004-06-03 | The Johns Hopkins University | Human embryonic stem cell cultures, and compositions and methods for growing same |
UA59678A (uk) | 2002-11-15 | 2003-09-15 | Національний Медичний Університет Ім. О.О. Богомольця | Спосіб лікування ревматоїдного артриту |
WO2004081172A2 (en) * | 2003-03-12 | 2004-09-23 | Reliance Life Sciences Pvt. Ltd. | Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells |
JP2007503811A (ja) | 2003-08-29 | 2007-03-01 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | 霊長類胚幹細胞からの神経幹細胞、運動ニューロン及びドーパミンニューロンのinvitroでの分化の方法 |
WO2005047524A2 (en) | 2003-11-10 | 2005-05-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
WO2005052138A1 (en) | 2003-11-19 | 2005-06-09 | Wisconsin Alumni Research Foundation | Cryopreservation of pluripotent stem cells |
UA71388A (uk) | 2003-12-26 | 2004-11-15 | Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України | Спосіб отримання збагаченої суспензії стовбурових нейральних клітин |
WO2005065354A2 (en) | 2003-12-31 | 2005-07-21 | The Burnham Institute | Defined media for pluripotent stem cell culture |
GB2441530B (en) | 2004-02-12 | 2009-09-23 | Univ Newcastle | Stem Cells |
WO2005099758A2 (en) * | 2004-04-17 | 2005-10-27 | The Board Of Trustees The Leland Standford Junior University | Injectable bioartificial tissue matrix |
WO2006044204A2 (en) | 2004-10-05 | 2006-04-27 | University Of Georgia Research Foundation, Inc. | Neuronal progenitors from feeder-free human embryonic stem cell culture |
MY154677A (en) | 2006-03-07 | 2015-07-15 | Shroff Geeta | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
-
2007
- 2007-03-06 MY MYPI20083447A patent/MY154677A/en unknown
- 2007-03-06 EP EP07789615.7A patent/EP1993575B1/en active Active
- 2007-03-06 EA EA200801943A patent/EA027648B9/ru not_active IP Right Cessation
- 2007-03-06 DK DK07789615.7T patent/DK1993575T3/da active
- 2007-03-06 WO PCT/IB2007/002292 patent/WO2007141657A2/en active Application Filing
- 2007-03-06 GE GEAP200710928A patent/GEP20135796B/en unknown
- 2007-03-06 EP EP11190554A patent/EP2422798A3/en not_active Withdrawn
- 2007-03-06 NZ NZ571127A patent/NZ571127A/en unknown
- 2007-03-06 NZ NZ594639A patent/NZ594639A/xx active IP Right Revival
- 2007-03-06 KR KR1020087024426A patent/KR101505202B1/ko active IP Right Grant
- 2007-03-06 US US12/224,839 patent/US10545135B2/en active Active
- 2007-03-06 CN CNA200780013128XA patent/CN101420964A/zh active Pending
- 2007-03-06 EP EP11190549A patent/EP2422797A3/en not_active Withdrawn
- 2007-03-06 AP AP2008004623A patent/AP2949A/xx active
- 2007-03-06 KR KR1020147030666A patent/KR101505382B1/ko active IP Right Grant
- 2007-03-06 CN CN201410100237.7A patent/CN103893211A/zh active Pending
- 2007-03-06 EP EP11190565A patent/EP2422800A3/en not_active Withdrawn
- 2007-03-06 MX MX2008011279A patent/MX347303B/es active IP Right Grant
- 2007-03-06 BR BRPI0708576-1A patent/BRPI0708576A2/pt not_active Application Discontinuation
- 2007-03-06 AU AU2007257594A patent/AU2007257594B2/en active Active
- 2007-03-06 JP JP2008557853A patent/JP5649786B2/ja active Active
- 2007-03-06 EP EP11190533A patent/EP2422795A3/en not_active Withdrawn
- 2007-03-06 EP EP11190577A patent/EP2422802A3/en not_active Withdrawn
- 2007-03-06 EP EP11190542A patent/EP2422796A3/en not_active Withdrawn
- 2007-03-06 EP EP11190572A patent/EP2422801A3/en not_active Withdrawn
- 2007-03-06 CA CA2644922A patent/CA2644922C/en active Active
- 2007-03-06 EP EP11190560A patent/EP2422799A3/en not_active Withdrawn
- 2007-03-06 EP EP11190582A patent/EP2422803A3/en not_active Withdrawn
- 2007-03-06 EP EP11190528A patent/EP2422794A3/en not_active Withdrawn
-
2008
- 2008-08-26 IL IL193702A patent/IL193702A/en active IP Right Grant
- 2008-09-05 CU CU2008000161A patent/CU20080161A7/es unknown
- 2008-10-03 MA MA31267A patent/MA30323B1/fr unknown
- 2008-10-06 CR CR10345A patent/CR10345A/es not_active Application Discontinuation
- 2008-10-06 NO NO20084181A patent/NO20084181L/no unknown
- 2008-10-07 EC EC2008008799A patent/ECSP088799A/es unknown
-
2013
- 2013-01-07 US US13/735,281 patent/US8592208B2/en active Active
- 2013-01-07 US US13/735,294 patent/US9383349B2/en active Active
- 2013-10-23 US US14/061,420 patent/US8900861B2/en active Active
- 2013-10-24 US US14/062,512 patent/US9482660B2/en active Active
- 2013-10-25 US US14/063,606 patent/US9488643B2/en active Active
- 2013-10-25 US US14/063,573 patent/US9804151B2/en active Active
- 2013-10-31 US US14/068,252 patent/US9134299B2/en active Active
-
2014
- 2014-04-22 JP JP2014087839A patent/JP2014159455A/ja active Pending
- 2014-05-06 PH PH12014501028A patent/PH12014501028A1/en unknown
-
2018
- 2018-11-29 US US16/204,601 patent/US20190369088A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501028A1 (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
KR102388828B1 (ko) | 콜로니 형성 배지 및 그 용도 | |
KR102022538B1 (ko) | 에델바이스 추출물을 포함하는 피부 재생 및 모발 성장 촉진제 | |
KR101757827B1 (ko) | 때죽나무(Styrax japonica) 추출물을 유효성분으로 포함하는 히알루로니다아제(HAase, hyaluronidase) 저해제 및 이를 포함하는 항염증 및 항알레르기 조성물 | |
EP2977446A1 (en) | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method | |
UA99813C2 (ru) | Композиция человеческих эмбриональных стволовых клеток или их производных, способы применения и способы получения (варианты) | |
KR20160006127A (ko) | 줄기세포의 보관 안정성 증진용 조성물 | |
JP6583679B2 (ja) | 酵母抽出物を用いた幹細胞の未分化状態維持剤及び増殖促進剤 | |
KR101902425B1 (ko) | 치자 추출물을 포함하는 재생 촉진제 | |
JP2016202098A (ja) | マンネンタケ抽出物を用いた幹細胞の未分化状態維持剤及び増殖促進剤 | |
EP4089164A1 (en) | Composition for reinforcing function of stem cell | |
KR20150066224A (ko) | Ycg063을 함유하는 암전이 억제용 조성물 | |
KR101999842B1 (ko) | 지방유래 줄기세포 추출물을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물 | |
KR101644964B1 (ko) | 페리오스틴 유래 펩타이드를 유효성분으로 포함하는 혈관신생 촉진용 조성물 | |
WO2005056780A3 (en) | Cell culture with nm23, cell culture media comprising nm23 and therapeutic use of cells cultured in the presence of nm23. | |
Jayawardana et al. | Protease inhibitory activity of some medicinal plants in Sri Lanka | |
KR101835180B1 (ko) | 재조합 BTG2(B cell translocation gene 2) 단백질 및 이의 생산방법 | |
Marasović et al. | Dietary intake and antitumour preventive properties of 2, 4, 6-trifluorophenylboronic acid in mice: Some results and prospects | |
WO2010037826A3 (en) | Method of enriching stem cells in culture | |
KR20220073565A (ko) | 천연물 추출물 전처리 줄기세포 유래 엑소좀을 포함하는 신경질환 치료용 조성물 및 이의 용도 | |
JP6840376B2 (ja) | 幹細胞の未分化状態維持剤及び増殖促進剤 | |
JP2015228855A (ja) | 幹細胞の未分化状態維持剤及び増殖促進剤 | |
KR20150146097A (ko) | 때죽나무(Styrax japonica) 추출물을 유효성분으로 포함하는 히알루로니다아제(HAase, hyaluronidase) 저해제를 포함하는 항염증 조성물 | |
Sheikhpour et al. | 0TAntiproliferative effects 0T5T of 5T Ectoine and Hydroxyectoine 5 Ton human 0T5Tlung cancer cells. I | |
AU2013206647A1 (en) | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |